Hofseth BioCare

About Hofseth BioCare

Hofseth BioCare is a Norwegian consumer and pet health company that upcycles salmon side streams into high-value ingredients and finished products. The company says it has spent 15 years on research, technology, and product development, and that its products have evolved from animal feed applications into exclusive supplements and human-grade ingredients.

It positions itself as a science-led business built on proprietary enzymatic hydrolysis technology, with a focus on preserving the quality of lipids, proteins, and calcium from fresh salmon off-cuts. Hofseth BioCare says its products are sold in 40 countries and are supported by ongoing clinical and pre-clinical research in multiple countries and institutions.

The company serves both nutrition and health markets, including human health, pet health, and broader medical-nutrition applications. Its market message combines sustainability, traceability, and resource efficiency with a pipeline that extends from consumer ingredients to potential future medical uses.

Core Values

• Sustainability: The company frames sustainability as central to its business model, turning salmon by-products that were once treated as waste into health ingredients for people and pets.
• Optimal use of natural resources: Hofseth BioCare emphasizes upcycling and efficient use of aquaculture side streams, aiming to extract more value from each raw material stream.
• Traceability: The company highlights full traceability and close control of sourcing and processing, supported by its own supply relationships and Norwegian production sites.
• Science and innovation: Its value proposition is built around proprietary technology, patents, and ongoing research, with a strong emphasis on clinical evidence and product development.

Unique Aspects

• Patented enzymatic hydrolysis platform: Hofseth BioCare says it has invented and patented a unique enzymatic hydrolysis process that preserves micro-components and enables human-grade ingredients from fresh salmon off-cuts.
• Integrated Norwegian production footprint: The company operates processing facilities in Midsund and Berkåk, giving it control over the protein value chain from raw material sourcing through to final product.
• Global commercial reach: Its products are sold in 40 countries, and the company also notes a broad international presence through offices in cities including Oslo, Zürich, London, Chicago, Mumbai, Singapore, Tokyo, and Menlo Park.
• Research-led pipeline: The company has ongoing clinical and pre-clinical programs with partners such as Stanford School of Medicine, KGK Science, the Norwegian School of Sport Sciences, the National University of Singapore, and St. Xavier's College.
• Recent capital and capacity support: Known news reports a 2026 private placement that raised gross proceeds of approximately NOK 144.5 million, intended to strengthen the balance sheet and support growth, R&D, and capacity expansion.